World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 17 October 2016
Main ID:  ISRCTN46820623
Date of registration: 18/09/2012
Prospective Registration: No
Primary sponsor: University of Birmingham (UK)
Public title: Accuracy of Bladder Ultrasound Study (BUS)
Scientific title: Accuracy of Bladder Ultrasound in the diagnosis of Detrusor Overactivity (DO): a study to evaluate if ultrasound can reduce the need for urodynamics
Date of first enrolment: 01/04/2011
Target sample size: 600
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN46820623
Study type:  Observational
Study design:  Diagnostic (test accuracy) study (Diagnostic)  
Phase:  Not Applicable
Countries of recruitment
United Kingdom
Contacts
Name: Pallavi    Latthe
Address:  Birmingham Women's Hospital Metchley Drive Edgbaston B15 2TT Birmingham United Kingdom
Telephone: +44 (0)121 627 2672
Email: Pallavi.Latthe@bwhct.nhs.uk
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Frequency of 9 or more voids in 24 hours as reported in the 3 day bladder diary at least on one of the days
2. Mild - severe urgency (cannot defer the urge to void) on at least one occasion in 3 day bladder diary
3. Post void residual volume <100 mls on screening
4. Written informed consent
5. If patient has had previous stress incontinence surgery &/or Botox, it was >6 months ago

Exclusion criteria: 1. Pregnancy and up to 6 weeks postpartum
2. Pure symptoms of stress incontinence or stress predominant mixed incontinence
3. Evidence of cystitis (dipstick positive for leucocytes/nitrites)
4. Voiding difficulties (post void residual >100 ml)
5. Prolapse > grade II (any compartment)
6. Urodynamics, assessment in the past 6 months
7. Use of antimuscarinics for more than 6 months continuously.
8. Current use of anti-muscarinics (e.g. Tolterodine, solifenacin, oxybutynin). If the woman is taking anti-muscarinics at the point of consent, she will be eligible if medication is ceased immediately
9. There is a delay of at least 2 weeks until the index and reference tests are carried out.


Age minimum:
Age maximum:
Gender: Female
Health Condition(s) or Problem(s) studied
Overactive bladder syndrome
Urological and Genital Diseases
Other specified disorders of bladder
Intervention(s)
The bladder wall thickness will be obtained by means of an ultrasound examination. In order to perform this scan it is necessary to gently insert the tip of an ultrasound probe into the vagina. This is a simple and usually painless procedure.

For reference standard, UDS will be performed on all patients for DO verification.
Primary Outcome(s)
The BUS testing procedure will be standardised in the first phase of the study and criteria for interpretation have been determined a priority. The first objective of the study is to determine the accuracy of BUS in the diagnosis of DO. To do this, the comparison of BUS against UDS will be made and estimates of sensitivity, specificity, predictive values, likelihood ratios and their 95% confidence intervals calculated.
Secondary Outcome(s)
To investigate the value added by BUS to information already obtained from routinely used initial non-invasive tests (history, bladder diary, urine dipstick).
Secondary ID(s)
HTA 09/22/122, Version 5.0
Source(s) of Monetary Support
Health Technology Assessment Programme
Secondary Sponsor(s)
Birmingham Women's NHS Foundation Trust (UK)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history